Suraksha Diagnostic's Quality Grade Upgrade Reflects Strong Financial Performance and Stability

Suraksha Diagnostic has recently undergone an evaluation revision, reflecting its strong performance metrics within the healthcare services sector. The company has demonstrated notable sales growth over the past five years, achieving a rate of 14.50%. Additionally, its EBIT growth during the same period stands at an impressive 89.29%, indicating robust operational efficiency.
Financial stability is underscored by a favorable EBIT to interest ratio of 3.86 and a unique position with negative net debt, complemented by a net debt to equity ratio of 0.00. The company's tax ratio is reported at 23.76%, while institutional holding is at 36.32%, suggesting a solid backing from institutional investors.

In comparison to its peers, Suraksha Diagnostic holds a competitive edge, with several competitors in the healthcare services industry rated lower in quality. For instance, Aster DM Healthcare is noted for its below-average performance, while other companies like Dr. Lal Pathlabs and Krishna Institute maintain good ratings. This context highlights Suraksha's favorable standing in a competitive landscape, emphasizing its strong financial metrics and market position.